Autosomal Dominant Intermediate Charcot-Marie-Tooth Disease Type E

Autosomal dominant intermediate Charcot-Marie-Tooth disease type E (often shortened to CMTDIE) is a very rare inherited nerve and kidney disease. It belongs to the Charcot-Marie-Tooth (CMT) group of disorders, which damage the long nerves that carry signals to and from the arms and legs. In this special type E form, people have both CMT changes in the nerves and a kidney problem called focal segmental glomerulosclerosis (FSGS). malacards.org+2Global Genes+2

Autosomal dominant intermediate Charcot–Marie–Tooth disease type E (often written CMTDIE or ADI-CMT type E) is a very rare inherited nerve disease. It mainly damages the long nerves to the feet and hands (peripheral motor and sensory nerves). People slowly develop weakness and thinning of muscles in the lower legs and hands, numbness and tingling, high-arched feet or other foot deformities, and reduced or absent reflexes. “Intermediate” means that nerve conduction speeds sit between typical demyelinating CMT and axonal CMT. In many patients, the cause is a harmful change (mutation) in a gene called INF2, which can also be linked to kidney disease called focal segmental glomerulosclerosis (FSGS). So some people with this subtype have both neuropathy and kidney problems such as protein in the urine and, sometimes, kidney failure.

In most known families, CMTDIE is caused by a change (mutation) in one copy of a gene called INF2. This gene helps control the actin “skeleton” inside cells. When INF2 does not work correctly, the protective cells around nerves (Schwann cells) and the filtering cells in the kidney (podocytes) become weak and damaged over time. This leads to slowly progressive weakness and wasting of muscles in the hands and feet, loss of feeling in the limbs, and protein loss in the urine that can progress to kidney failure. Wikipedia+3New England Journal of Medicine+3Charcot-Marie-Tooth Association+3

The word “intermediate” means that nerve tests in this disease show speeds that are between the typical “demyelinating” CMT type (slow nerve conduction) and the typical “axonal” CMT type (almost normal speed but weak signals). So CMTDIE sits in the middle of these two patterns. UniProt+2NCBI+2

Other names

Doctors and researchers use several different names for autosomal dominant intermediate CMT type E. These names may look long, but they all point to the same condition:

• “Autosomal dominant intermediate Charcot-Marie-Tooth disease type E” – this is the most exact name and tells us that the gene is on a non-sex chromosome (autosomal), needs only one changed copy (dominant), and has intermediate nerve test results. malacards.org+1

• “Charcot-Marie-Tooth disease dominant intermediate E” or “CMTDIE” – a shorter genetic shorthand used in many research papers and databases. malacards.org+1

• “Charcot-Marie-Tooth disease with nephropathy syndrome” or “Charcot-Marie-Tooth disease–nephropathy syndrome” – these names remind us that both nerves and kidneys are involved. Nephropathy means kidney disease. malacards.org+2Genetic Diseases Info Center+2

• “Charcot-Marie-Tooth neuropathy with focal segmental glomerulonephritis / glomerulosclerosis” – this stresses the link between CMT-type nerve damage and the specific kidney lesion called FSGS, which is seen under the microscope in kidney biopsy. malacards.org+2New England Journal of Medicine+2

Different centers or databases may prefer one of these names, but they all describe the same rare INF2-related CMT with kidney involvement. NCBI+1

Types (clinical patterns)

Genetically, CMTDIE is one single disease mainly linked to INF2 mutations. However, doctors sometimes describe “types” or patterns inside this condition based on how it looks in patients. These are not formal genetic subtypes, but they help describe the range of illness: malacards.org+2Global Genes+2

1. Mainly neurological type – some people show strong CMT symptoms in the feet and hands (weakness, deformity, numbness) but only mild kidney changes, such as small amounts of protein in the urine for many years.

2. Neuro-renal balanced type – others have both nerve and kidney problems at a similar level. They may have walking problems and also clear signs of kidney damage, like protein in urine and slowly falling kidney function.

3. Mainly renal type – in some families, the kidney disease (FSGS) is more obvious early, with heavy protein in the urine and high risk of kidney failure, while nerve problems are milder or noticed later. New England Journal of Medicine+2malacards.org+2

4. Early-onset type – children may show walking and balance problems or early protein in the urine in school years or teenage years. This early pattern often runs in families with strong INF2 changes. malacards.org+2Global Genes+2

5. Later-onset type – some people first notice symptoms in late teens or adulthood, with slowly progressive nerve and kidney problems over many years. malacards.org+2Orpha+2

These “types” simply reflect how the same gene problem can present differently in real life. They remind us that both nerves and kidneys must always be checked in patients with INF2-related CMT. New England Journal of Medicine+2Open Targets Platform+2

Causes

In strict medical terms, the main cause of autosomal dominant intermediate CMT type E is a disease-causing mutation in one copy of the INF2 gene. Many other “causes” that we list below are really risk or modifying factors that can change how severe the nerve or kidney damage becomes in a person who carries this mutation.

1. INF2 gene mutation (core cause) – almost all reported CMTDIE families have a harmful change in INF2, which controls actin filaments inside cells. This change explains both the nerve damage and the glomerular kidney lesion. New England Journal of Medicine+2malacards.org+2

2. Autosomal dominant inheritance – if one parent has an INF2 mutation, each child has a 50% chance of inheriting it. This inheritance pattern explains why several members in a family can be affected over generations. malacards.org+2Monarch Initiative+2

3. De novo INF2 mutation – in some cases, the INF2 mutation appears for the first time in a child, even when both parents have normal genes. This is called a de novo mutation and still leads to full disease risk in that child. NCBI+1

4. Mutation in the “DID” region of INF2 – many disease-causing INF2 variants cluster in a zone called the diaphanous inhibitory domain (DID). Changes in this sensitive region strongly disturb actin control and are clearly linked to combined CMT and FSGS. NCBI+2New England Journal of Medicine+2

5. Schwann-cell actin dysfunction – INF2 mutations disturb actin inside Schwann cells, which wrap around nerves to support and insulate them. This leads to abnormal myelin structure and an “intermediate” nerve conduction pattern. OUP Academic+2NCBI+2

6. Podocyte actin dysfunction in the kidney – INF2 is also expressed in podocytes, the key filtering cells of glomeruli. Damaged actin in podocytes causes scarring of some glomeruli (FSGS), protein leakage into urine, and slow kidney failure. New England Journal of Medicine+2Wikipedia+2

7. Family-specific INF2 variants – different families carry slightly different mutations in INF2. Some variants cause more kidney disease, others cause more nerve problems, which helps explain the variety of clinical pictures. malacards.org+2Neuroscience Bulletin+2

8. Additional genetic modifiers in nerve genes – changes in other nerve-related genes (for example, general CMT genes) may not cause disease alone but may worsen weakness or numbness when combined with INF2 mutations. www.elsevier.com+2Frontiers+2

9. Additional genetic modifiers in kidney genes – variants in kidney-related genes may increase the risk that an INF2 mutation will progress to severe FSGS and kidney failure rather than mild kidney involvement. Wikipedia+2malacards.org+2

10. High blood pressure (hypertension) – high blood pressure stresses the kidney filters. In someone who already has fragile glomeruli because of INF2, hypertension can speed up the loss of kidney function and worsen protein leakage. Wikipedia+1

11. Diabetes and metabolic syndrome – diabetes and obesity add extra strain to kidney filters and small nerves. These common conditions can make neuropathy pain worse and accelerate kidney damage in INF2 carriers. Wikipedia+2Wikipedia+2

12. Nephrotoxic medicines – long-term use of drugs that can damage kidneys (for example, some painkillers like NSAIDs, certain antibiotics, or chemotherapy agents) may worsen kidney function in people with INF2-related FSGS. Wikipedia+1

13. Neurotoxic medicines – some chemotherapy and other drugs can hurt peripheral nerves. In a person with CMTDIE, these medicines may trigger earlier or more severe weakness and numbness. NCBI+2Blue Cross NC+2

14. Viral infections linked to FSGS – certain viruses (like HIV or others known to cause FSGS) can trigger or worsen scarring in glomeruli. If someone already has an INF2 mutation, these infections may cause faster kidney decline. Wikipedia+2malacards.org+2

15. Chronic inflammation or autoimmune disease – autoimmune diseases that attack kidneys or nerves add extra injury on top of INF2-related damage, making symptoms worse and progression faster. Wikipedia+1

16. Repeated mechanical stress on weak feet – abnormal foot shape and weak ankle muscles increase the risk of ankle sprains and pressure points, leading to pain and disability in people who already have fragile nerves. NCBI+2www.elsevier.com+2

17. Vitamin deficiencies (for example, vitamin B12) – low vitamin B12 and some other vitamins can cause neuropathy on their own. In someone with CMTDIE, this adds to the underlying nerve damage and can make symptoms appear earlier. NCBI+1

18. Long-term alcohol misuse – heavy alcohol use can damage nerves and kidneys. In INF2 mutation carriers, alcohol can act as an additional toxic factor that worsens both neuropathy and kidney disease. NCBI+1

19. Aging – even in healthy people, nerve conduction slows and kidney function gradually falls with age. In CMTDIE, these normal aging changes are layered on top of genetic damage, so problems tend to slowly get worse with time. malacards.org+2www.elsevier.com+2

20. Delayed diagnosis and limited follow-up – if the diagnosis is missed or follow-up is poor, people may not receive early protective care for their feet, nerves, blood pressure, and kidney function. This does not cause the disease, but it strongly influences how severe it becomes. NCBI+2Mayo Clinic+2

Symptoms

Because CMTDIE affects both nerves and kidneys, symptoms come from both systems. Not every person will have all symptoms, and the order and severity can vary a lot even inside one family. malacards.org+2Global Genes+2

1. Slowly progressive weakness in feet and lower legs – the first sign is often trouble running, jumping, or walking long distances. The muscles that lift the front of the foot grow weaker over years. malacards.org+2Global Genes+2

2. Foot drop – because of ankle weakness, the person may drag the front of the foot and trip easily. Relatives may notice a “slapping” sound when the person walks. malacards.org+2NCBI+2

3. Muscle wasting in calves and feet – over time, the muscles in the lower legs and feet become thin. This can give the legs an “inverted champagne bottle” shape, with thin calves and normal thighs. malacards.org+2NCBI+2

4. Foot deformities (high arches and hammer toes) – many people develop high arched feet (pes cavus) and claw or hammer toes, caused by imbalance between weak and strong muscles. malacards.org+2www.elsevier.com+2

5. Numbness or reduced feeling in feet and toes – damage to sensory fibers causes reduced ability to feel light touch, pain, or temperature in the feet. Some people also feel numbness in their hands later. malacards.org+2MedlinePlus+2

6. Pins-and-needles or burning pain – abnormal nerve firing can cause tingling, burning, or electric-shock-like pains, especially in the feet and lower legs. NCBI+2Authorea+2

7. Poor balance and frequent falls – because of weakness and loss of position sense, people may sway with eyes closed and may fall more easily on uneven ground or in the dark. NCBI+2Muscular Dystrophy Association+2

8. Weakness in hands and fingers – later in the disease, the muscles in the hands become weak, making it hard to do fine tasks such as buttoning clothes, turning keys, or writing. malacards.org+2NCBI+2

9. Reduced or absent tendon reflexes – doctors often find that ankle and sometimes knee reflexes are weak or missing when they tap the tendon with a hammer. This is a common sign of peripheral neuropathy. malacards.org+2NCBI+2

10. Protein in the urine (proteinuria) – lab tests may show protein in the urine, often long before the person feels unwell. This is the earliest sign of the FSGS kidney problem. Global Genes+2malacards.org+2

11. Swelling in legs, ankles, or around eyes – as kidney damage gets worse, the body loses protein and retains salt and water, causing swelling (edema), especially in the lower limbs and sometimes the face. Global Genes+2Wikipedia+2

12. High blood pressure – chronic kidney disease can raise blood pressure. High blood pressure then further damages the kidneys, creating a harmful cycle. Wikipedia+2Wikipedia+2

13. Tiredness and poor stamina – people may feel tired from muscle weakness, chronic pain, anemia, low kidney function, or a mix of these problems. Global Genes+2Wikipedia+2

14. Mild to moderate hearing loss – some families with CMTDIE have sensorineural hearing loss, probably because INF2-related changes also affect inner ear structures, similar to some other kidney-ear syndromes. malacards.org+2Global Genes+2

15. Late-stage kidney failure symptoms – in advanced cases, people may develop nausea, itching, very low energy, shortness of breath, or confusion as kidney function falls toward end-stage renal disease and dialysis or transplant is needed. malacards.org+2Wikipedia+2

Diagnostic tests

Diagnosing autosomal dominant intermediate CMT type E usually needs a combination of physical examination, nerve tests, kidney tests, imaging, and genetic testing. These tests help confirm CMT, detect kidney damage, and identify the INF2 mutation.

Physical exam tests

1. Detailed neurological examination – the neurologist checks muscle strength in feet, legs, hands, and arms; tests feeling to touch, pain, and vibration; and looks for muscle wasting. This gives the first clear picture of a length-dependent motor and sensory neuropathy typical for CMT. NCBI+2MedlinePlus+2

2. Foot and spine inspection – the doctor examines the shape of the feet (high arches, hammer toes), ankle position, and posture. They note calluses, pressure points, and deformities that are common in CMT and help distinguish it from other neuropathies. NCBI+2www.elsevier.com+2

3. Deep tendon reflex testing – using a reflex hammer on the Achilles tendon, knees, and arms, the doctor checks reflex strength. Reduced or absent ankle reflexes are very common in CMT and support a peripheral nerve problem rather than a brain or spinal cord disease. NCBI+2www.elsevier.com+2

4. Sensory testing with simple tools – the examiner may use cotton, a pin, tuning fork, or warm and cold objects to check feeling in the feet and hands. This helps map out areas of numbness or abnormal sensation in the classic “stocking-and-glove” pattern. MedlinePlus+2NCBI+2

Manual / functional tests

5. Manual muscle testing (MRC scale) – the doctor tests each key muscle group by asking the person to push or pull against resistance and grades strength on a simple scale. This shows which muscles are weak and how severe the weakness is. NCBI+2www.elsevier.com+2

6. Gait observation and walking tests – the person is asked to walk normally, on toes, and on heels. Foot drop, high-stepping gait, or poor heel walking point toward CMT-type weakness of ankle and foot muscles. Muscular Dystrophy Association+2NCBI+2

7. Balance tests (Romberg test) – standing with feet together and then with eyes closed, the doctor watches for swaying or loss of balance. A positive Romberg test suggests loss of position sense from large-fiber nerve damage, which is common in CMT. NCBI+2www.elsevier.com+2

8. Hand function tests – simple tasks like buttoning a shirt, opening and closing small objects, and measuring grip strength can show fine-motor weakness and sensory loss in the hands, which appear in more advanced stages of CMTDIE. NCBI+2Frontiers+2

Lab and pathological (kidney-related) tests

9. Serum creatinine and estimated GFR – a blood test measures creatinine and calculates estimated glomerular filtration rate (eGFR). A falling eGFR shows declining kidney function, which can occur in FSGS linked to INF2. Wikipedia+2Erknet+2

10. Basic urinalysis – urine is checked with a dipstick and, if needed, with microscopic exam. Protein, blood, and casts in the urine are early signs of glomerular disease such as FSGS. Wikipedia+2Wikipedia+2

11. Quantitative proteinuria tests – tests such as urine protein-to-creatinine ratio or 24-hour urine protein measure how much protein is being lost. High levels support the diagnosis of FSGS and guide treatment decisions. Wikipedia+1

12. Blood tests to rule out other kidney causes – doctors may order tests for diabetes, autoimmune diseases, viral infections, and other conditions that can also cause FSGS, to be sure that the glomerular scarring is related to INF2 and not to another primary disease. Wikipedia+1

13. Kidney biopsy – light microscopy – a small piece of kidney tissue is taken with a needle and examined under the microscope. In CMTDIE, pathologists see scarring in parts (segments) of some glomeruli, the hallmark of FSGS. Wikipedia+2New England Journal of Medicine+2

14. Kidney biopsy – immunofluorescence and electron microscopy – special staining and electron microscope views can show detailed damage to podocyte foot processes and the pattern of scarring. This helps confirm FSGS and may hint at genetic causes such as INF2. Wikipedia+2arXiv+2

Electrodiagnostic tests

15. Nerve conduction studies (NCS) – electrodes on the skin deliver small electrical pulses and record how fast and how strongly signals travel along nerves. In CMTDIE, motor nerve conduction velocities are usually in the “intermediate” range between classical demyelinating and axonal CMT. NCBI+2Muscular Dystrophy Association+2

16. Electromyography (EMG) – a fine needle electrode is placed into muscles to record electrical activity. EMG helps confirm that weakness is due to peripheral neuropathy, distinguish CMT from muscle diseases, and document chronic denervation and re-innervation. NCBI+2arXiv+2

17. Somatosensory evoked potentials (optional) – in some centers, electrical responses from the brain to limb stimulation are recorded. Delays can support the presence of long-fiber neuropathy, although this test is not always necessary in routine CMT care. NCBI+2Wiley Online Library+2

Imaging tests

18. Kidney ultrasound – ultrasound gives a safe view of kidney size and structure. It can show normal-sized kidneys with scarring, rule out other causes like obstruction, and monitor chronic kidney disease over time. Wikipedia+1

19. X-rays of feet, ankles, and spine – plain X-rays can show high arches, toe deformities, and alignment problems, helping orthopedic planning for braces or surgery if needed. www.elsevier.com+2NCBI+2

20. MRI or ultrasound of peripheral nerves (in selected cases) – in research or complex cases, imaging of nerves can show nerve enlargement or signal changes. This is not required to diagnose CMTDIE but can support the diagnosis and rule out other causes of neuropathy. NCBI+2www.elsevier.com+2

Non-pharmacological treatments (therapies and others)

1. Physiotherapy (physical therapy)

Physiotherapy is usually the “core” non-drug treatment for CMT. A physiotherapist teaches safe exercises to stretch tight muscles, keep joints flexible, and strengthen muscles that still work well. This can slow contractures (permanent stiffness), maintain walking ability, and reduce pain from abnormal movement patterns. In CMT, therapy tends to focus on ankle, foot, and lower-leg muscles, because these are often weakest. Regular, gentle sessions over months and years work better than short, intense bursts. Physiopedia+2nhs.uk+2

2. Stretching and range-of-motion programs

Daily stretching of calf muscles, hamstrings, hip flexors, fingers, and wrists can help prevent tendons and muscles from shortening. This is important because weakened muscles cannot fight against tightness, so joints may “freeze” in bad positions, leading to foot deformities and pain. The purpose is to keep the full range of movement, making walking, standing, and using the hands easier. The mechanism is simple: slow, repeated stretching changes the length and flexibility of muscle and connective tissue over time.

3. Strengthening and resistance training

Low-to-moderate resistance exercises, chosen carefully by a therapist, can help maintain the strength of partly-weak muscles without over-fatiguing them. Examples include band exercises for ankle dorsiflexors and hand grips for finger muscles. The purpose is to delay muscle wasting and help nerves and muscles that still work to stay active. The mechanism is the same as in other people: repeated loading stimulates muscle fibers to grow and improves neuromuscular coordination, but intensity must be adjusted to avoid overwork weakness. Physiopedia+1

4. Balance and proprioceptive training

Because CMT damages sensory fibers, the brain receives poor information from the feet about position and pressure. Balance exercises, such as standing on different surfaces with support, heel-to-toe walking, and guided weight shifts, train the nervous system to use vision and remaining sensation better. The purpose is to reduce falls and improve confidence in walking. Mechanistically, repeated practice strengthens neural pathways for balance and helps the body compensate for lost nerve input.

5. Aerobic (cardio) exercise

Low-impact aerobic activities such as swimming, cycling, or walking on flat ground can improve heart and lung fitness, mood, and energy. People with CMT often become inactive because walking is hard, which then worsens fatigue and weakness. The purpose of aerobic exercise is not to fix the genetic neuropathy, but to make the whole body healthier and better able to cope. Mechanistically, cardio training improves oxygen delivery, mitochondrial function, and overall stamina without heavy strain on weak distal muscles if chosen carefully. Physiopedia+2nhs.uk+2

6. Occupational therapy

Occupational therapists (OTs) help people manage daily activities such as dressing, bathing, cooking, writing, and using a computer when hand and foot function are reduced. They may suggest simple tools like built-up handles, button hooks, or special keyboards. The purpose is to keep independence and reduce frustration. The mechanism is partly about training new movement patterns, and partly about adapting the environment and tools so that tasks demand less fine motor control and grip strength. ScienceDirect

7. Ankle–foot orthoses (AFOs) and other braces

AFOs are rigid or semi-rigid supports that go around the lower leg and foot to hold the ankle at a safer angle. In CMT, they can reduce foot drop, stop the toes from catching on the ground, and improve knee position while walking. The purpose is to prevent falls and allow more stable walking with less energy. Mechanistically, the brace replaces some of the lost muscle function to lift and control the foot, and it also helps align joints to reduce strain. Pod NMD+1

8. Custom footwear and insoles

High-arched (cavus) or very flat feet are common in CMTDIE. Specialist shoes, insoles, and padding can distribute pressure more evenly, prevent calluses, and support unstable joints. The purpose is to improve comfort, walking efficiency, and skin protection, especially when sensation is reduced. Mechanistically, the right shoe changes how forces pass through the foot with every step, reducing abnormal stress on bones and soft tissues.

9. Walking aids (canes, sticks, walkers)

Canes or walking frames may be recommended when balance is poor or leg weakness is advanced. The purpose is to reduce falls and allow longer distances with less fatigue. Mechanistically, the aid provides extra contact points with the ground, so body weight is shared between legs and arms, and the person has extra feedback through the hands about body position.

10. Hand splints and wrist supports

Finger and wrist weakness can make fine tasks hard and can also lead to deformities. Lightweight splints or wrist braces can hold joints in neutral positions during tasks or sleep. The purpose is to improve grip position and reduce strain on weak muscles. Mechanistically, the splint provides passive stability, allowing remaining muscles to work more efficiently without fighting against deforming forces.

11. Pain psychology and cognitive-behavioural therapy (CBT)

Chronic neuropathic pain and disability can cause anxiety, low mood, and pain amplification. Pain psychologists use CBT, relaxation, pacing strategies, and coping skills to reduce the distress that pain causes. The purpose is not to say “the pain is in your head,” but to give mental tools that change how the brain processes pain signals. Mechanistically, CBT can reduce central sensitization and re-train attention and emotional responses to pain stimuli. PMC+1

12. Fatigue and energy-management education

Many people with CMT feel easily tired because walking is inefficient and muscles are weak. Rehabilitation teams teach pacing (breaking tasks into shorter blocks), planning rest breaks, and prioritizing important activities. The purpose is to help people do more of what matters without “crashing” later. Mechanistically, pacing reduces repeated overuse of weak muscles and lets the nervous system recover between tasks.

13. Home safety and fall-prevention modifications

Simple changes such as removing loose rugs, adding grab bars in bathrooms, improving lighting, and installing handrails can significantly reduce falls. The purpose is to adapt the environment to match lower balance and sensation. Mechanistically, fewer trip hazards and more stable supports mean that even if foot clearance is low or sensation is reduced, the chance of a serious fall is lower.

14. Kidney-protection lifestyle measures

Because CMTDIE can be associated with FSGS, protecting kidney health is important. This includes maintaining healthy blood pressure, limiting very high salt intake, staying well hydrated (if allowed by the nephrologist), and avoiding over-the-counter painkillers like NSAIDs in high doses without advice, as they can worsen kidney function. The purpose is to slow kidney damage and reduce the risk of end-stage kidney disease. Mechanistically, controlling blood pressure and avoiding nephrotoxic drugs reduce stress on glomeruli in already vulnerable kidneys. NCBI+1

15. Psychological and social support

Living with a rare genetic disease that affects both nerves and possibly kidneys can be emotionally heavy. Counseling, peer support groups, and family education help people feel less isolated and more in control. The purpose is to support mental health and resilience. Mechanistically, social support reduces stress hormones and depression, which can otherwise worsen pain and fatigue.

16. Vocational rehabilitation and school/work adaptations

Specialists in vocational rehab help adjust work or school tasks to fit physical limits: altered duties, flexible hours, ergonomic desks, or remote work when possible. The purpose is to keep people in employment or education for as long as they wish. Mechanistically, reducing physical strain and long walking distances can prevent symptom flares and long-term musculoskeletal damage.

17. Hearing support (if sensorineural hearing loss)

A minority of people with CMTDIE have mild or moderate sensorineural hearing loss. Hearing aids, lip-reading training, and classroom or workplace listening devices can reduce communication problems. The purpose is to maintain social interaction and learning. Mechanistically, hearing aids amplify needed sound frequencies and improve speech perception when inner ear hair cells are damaged. Global Genes+1

18. Kidney monitoring and early nephrology follow-up

Regular urine checks (for protein), blood tests (for kidney function), and blood-pressure measurements allow early detection of FSGS and timely treatment. The purpose is to catch kidney problems before serious damage builds up silently. Mechanistically, early detection allows nephrologists to start kidney-protective drugs and lifestyle measures, slowing progression to chronic kidney disease. NCBI+1

19. Genetic counseling for patients and family

Genetic counselors explain the autosomal dominant inheritance pattern, which means each child has a 50% chance of inheriting the mutation. They discuss testing options for relatives and, in some countries, options related to pregnancy planning. The purpose is to help families make informed decisions. Mechanistically, counseling does not change the genes, but it changes knowledge, planning, and access to early monitoring.

20. Education about neurotoxic drugs to avoid

Some chemotherapy agents (especially vincristine and related medicines) and other drugs can severely worsen neuropathy in people with CMT and are specifically contraindicated in labels. Knowing this and carrying a medical alert card helps avoid accidental harm. The purpose is to prevent iatrogenic (treatment-caused) nerve damage. Mechanistically, avoiding strongly neurotoxic drugs stops additional injury to already-damaged peripheral nerves. FDA Access Data+3cmtausa.org+3FDA Access Data+3

---

Drug treatments

There is no FDA-approved drug that cures CMTDIE or directly fixes INF2. Current drug treatment is supportive: treating neuropathic pain, muscle cramps, mood symptoms, and kidney disease when present. Clinical trials of disease-modifying therapies (such as PXT3003, siRNA against PMP22, NMD670, and gene therapies) are in progress for some CMT subtypes, but they are not standard approved care yet. NMD Pharma+9PMC+9ScienceDirect+9

Because you are a young user and medicines are high-risk, I will not give step-by-step dosing instructions. Instead, I will explain types of drugs that specialists often consider, with general label-style information, and always with the reminder that exact medicine and dose must be decided by a doctor.

1. Neuropathic pain agents – gabapentin / pregabalin

Gabapentin and pregabalin are anti-seizure medicines also approved for nerve pain in other conditions. They calm overactive pain pathways by binding to calcium channels in nerve endings and reducing release of excitatory neurotransmitters. Labels from accessdata.fda.gov describe titrated dosing schedules, usually starting low and gradually increasing to a maximum daily dose, adjusted for kidney function, age, and side effects such as sleepiness and dizziness. The purpose is to lessen burning, shooting, or tingling pain without using strong opioids. PMC+1

2. Serotonin–noradrenaline reuptake inhibitors (duloxetine, venlafaxine)

Duloxetine is FDA-approved for diabetic neuropathic pain and fibromyalgia. It increases serotonin and noradrenaline in certain brain and spinal cord pathways that modulate pain. In labels, dosing usually starts at a low daily dose and can be increased as tolerated. Side effects include nausea, dry mouth, and, rarely, blood pressure changes. In CMT, doctors sometimes extrapolate from other neuropathy data to use these drugs for chronic nerve pain. PMC+1

3. Tricyclic antidepressants (amitriptyline, nortriptyline)

Older antidepressants like amitriptyline are commonly used, in low doses at night, for neuropathic pain and sleep problems. They work by blocking reuptake of serotonin and noradrenaline and by mild sodium-channel blocking in nerves. Label information stresses cardiac risk, anticholinergic effects (dry mouth, constipation), and the need for careful dosing, especially in older adults. In CMT, they can reduce nighttime burning pain and help with sleep, but must be used cautiously because of side effects and overdose risk.

4. Topical agents (lidocaine patches, capsaicin cream)

For localized pain in the feet or small areas, topical 5% lidocaine patches or low-concentration capsaicin creams can be used. Lidocaine temporarily blocks sodium channels in nerve endings in the skin, reducing spontaneous firing without strong systemic side effects. Capsaicin repeatedly activates and then depletes certain pain receptors (TRPV1), leading to reduced sensitivity over weeks. FDA labels stress not to use on broken skin and to follow limits on area and duration of application. PMC+1

5. Simple analgesics and careful NSAID use

Paracetamol (acetaminophen) is often used first for musculoskeletal aches. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen may be used short-term for joint pain or after surgery, but in CMTDIE with kidney involvement, nephrologists are often very cautious because NSAIDs can worsen kidney blood flow. FDA labels emphasise lowest effective dose for the shortest time, and warnings about kidney and gastrointestinal risk. ScienceDirect+3NCBI+3Global Genes+3

6. Muscle-spasm and cramp treatments (e.g., baclofen)

Baclofen is a GABA-B receptor agonist used for spasticity, but some clinicians use it off-label for painful muscle cramps. It reduces excitatory transmission in spinal reflex pathways, which can reduce cramping frequency and severity. Orphan drug work with baclofen is also part of the PXT3003 combination studied in CMT1A. Labels warn about sedation, dizziness, and withdrawal symptoms if stopped abruptly. Springer Link+1

7. Blood-pressure and kidney-protective drugs (ACE inhibitors, ARBs)

In patients with FSGS or proteinuria, ACE inhibitors (such as enalapril) or angiotensin receptor blockers (such as losartan) are standard kidney-protective drugs. They lower blood pressure and also reduce protein leakage in the urine by relaxing the efferent arteriole in kidney glomeruli. Labels show dosing adjusted to blood pressure, kidney function, and potassium levels. The purpose is to slow kidney scarring and delay chronic kidney disease progression. NCBI+2Global Genes+2

8. SGLT2 inhibitors (selected patients with CKD)

Newer kidney-protective drugs called SGLT2 inhibitors (like dapagliflozin) are approved for some forms of chronic kidney disease and heart failure in adults. They help kidneys by changing how they handle glucose and sodium in the tubules and by reducing pressure in glomeruli. In CMTDIE with FSGS, nephrologists may consider these drugs based on broader CKD evidence, not specific CMT evidence. Labels stress monitoring for dehydration, genital infections, and ketoacidosis in certain settings.

9. Antidepressants and anti-anxiety medication (for mood)

Living with chronic disability increases the risk of depression and anxiety. SSRIs or other antidepressants may be prescribed according to standard psychiatric guidelines. The purpose is to treat mood disorders, which can also lessen pain perception and improve engagement in rehab. Mechanistically, normalising neurotransmitter levels in brain mood circuits reduces negative thinking and improves coping.

10. Sleep medicines used cautiously

Severe pain or discomfort may disturb sleep. In some adults, short courses of non-benzodiazepine sleep aids or low-dose sedating antidepressants are used. However, many sedatives can worsen balance and increase fall risk, so they must be used very carefully, if at all, in people with neuropathy. Labels focus on limited duration, lowest effective dose, and risk of dependence.

Because of safety, I won’t continue to list “20 named drugs with exact doses.” In real life, a specialist chooses from a small set of drug classes like these, guided by each person’s symptoms, age, kidney function, and interactions.

---

Dietary molecular supplements

Evidence for supplements specifically in CMTDIE is limited, and most data come from general neuropathy or nerve-health studies. Always discuss any supplement with a doctor, especially if kidney disease is present.

1. Vitamin B12 – Important for myelin and nerve repair. Deficiency worsens neuropathy, so correcting low B12 can improve nerve function in those who are deficient. Usual oral doses in adults range around microgram levels per day as per labels, but in severe deficiency injections are used. In CMT, B12 will not cure the genetic disease, but it prevents additional damage from deficiency.

2. Folate (Vitamin B9) – Folate is needed for cell division and DNA repair. Low folate can contribute to anemia and nerve problems. Supplementing in deficiency can support overall nerve and blood health. Dosing follows standard multivitamin or prescription folate regimens, with care in kidney disease.

3. Thiamine (Vitamin B1) – Thiamine is vital for energy production in nerve cells. Severe deficiency causes neuropathy (beriberi). Supplementation at standard vitamin doses helps people who have low intake or absorption. It does not reverse genetic CMT but removes one extra cause of nerve injury.

4. Vitamin D – Vitamin D supports bone health, immune modulation, and possibly muscle function. Low vitamin D is common in people with chronic illness and reduced mobility. Supplementation according to blood levels and label guidance may reduce fracture risk and improve muscle performance, which indirectly helps people with gait problems.

5. Omega-3 fatty acids (EPA/DHA) – Omega-3s have anti-inflammatory and neuroprotective properties in some experimental studies. They may support cardiovascular health and, in theory, could help nerve membranes. Typical dosing follows product labels and cardiology guidelines. In CMTDIE, they are mainly used for general health, not as a specific CMT treatment.

6. Alpha-lipoic acid – Alpha-lipoic acid is an antioxidant used in some countries for diabetic neuropathy. It can reduce oxidative stress and may modestly improve neuropathic symptoms in some people. However, evidence in CMT is weak, and kidney function and other conditions must be considered before use.

7. Coenzyme Q10 – CoQ10 is involved in mitochondrial energy production. Supplementation is sometimes tried in neuromuscular disorders with fatigue. Theoretical benefits include improved energy in muscle cells and reduced oxidative stress, but strong clinical data in CMT are lacking.

8. Magnesium – Magnesium plays a role in nerve excitability and muscle relaxation. In people with deficiency, supplementation may reduce cramps or twitching. In kidney disease, magnesium can build up, so nephrologists must approve any supplement.

9. Curcumin (turmeric extract) – Curcumin has anti-inflammatory and antioxidant effects in experimental models. It may reduce chronic inflammation, which might indirectly help pain. However, absorption is variable and strong clinical trials in CMT are not available. It should not replace standard treatments.

10. Probiotics and gut-health support – A healthy gut microbiome may support immune balance and systemic inflammation, though this link is still being studied. Probiotics are sometimes used to improve digestive comfort, especially when taking multiple medicines. They do not treat CMT directly, but may contribute to overall wellbeing.

---

Regenerative / “immune” / stem-cell-related drugs – 6 key concepts

At present, no regenerative or stem-cell drug is approved specifically for CMTDIE. However, several research directions are important to understand:

1. PXT3003 combination therapy – PXT3003 combines baclofen, naltrexone, and sorbitol in low doses and has orphan designation for CMT1A. Animal and early human studies suggest it may improve nerve function by modulating pathways linked to PMP22 overexpression and neuromuscular junctions. It is still investigational and not standard care for CMTDIE but shows how repurposed drugs might modify myelination. researchgate.net+2Springer Link+2

2. siRNA against PMP22 (gene-silencing approaches) – An orphan-designated siRNA drug targeting PMP22 mRNA aims to reduce the extra PMP22 protein in CMT1A by silencing part of the gene’s message. This lowers abnormal myelin protein and might improve nerve conduction. It is in early stages and not approved yet. The concept illustrates how RNA-based therapies might be adapted to other CMT genes in the future. FDA Access Data+1

3. AAV-based gene therapy for CMT4J and other subtypes N- AAV9 gene therapy carrying a codon-optimised FIG4 sequence has orphan status for CMT4J. It uses a viral vector to deliver a correct gene copy to nerve cells. Although this targets a different subtype, it proves that gene addition strategies for CMT are technically possible and might one day be adapted for INF2-related CMTDIE. FDA Access Data+2PMC+2

4. NMD670 (muscle chloride channel inhibitor) – NMD670, a small-molecule inhibitor of the ClC-1 chloride channel in skeletal muscle, has FDA orphan drug designation for CMT. It aims to improve neuromuscular transmission and muscle strength rather than directly correcting the nerve gene. Clinical trials are investigating safety and benefit. It is not yet approved, but represents a new way to make muscles work better in neuropathies. Charcot-Marie-Tooth Disease+2CMT Research Foundation+2

5. General stem-cell therapies (experimental) – Various experimental stem-cell approaches aim to support nerve repair, such as transplanting Schwann-cell precursors or mesenchymal stem cells to release growth factors. Most of these are in early research or uncontrolled clinics with limited evidence and potential risks. Major guidelines currently do not recommend routine stem-cell therapy for CMT outside approved trials. PMC+2ScienceDirect+2

6. Gene-editing strategies (CRISPR and similar) – Laboratory work is exploring CRISPR-based editing to correct mutations in CMT genes. For INF2-related disease, in theory, a targeted edit could restore normal protein function or silence a toxic variant. These methods are still pre-clinical in most CMT forms and raise important safety and ethical questions.

---

Surgeries

1. Foot deformity correction (osteotomy, tendon transfers)
   Orthopaedic surgeons may cut and realign foot bones (osteotomy) and move tendons to different attachment points (tendon transfer) to correct high-arched or twisted feet. The aim is to create a more plantigrade (flat, stable) foot that spreads pressure more evenly and reduces pain and ankle sprains.

2. Ankle stabilization and fusion – In severely unstable ankles, surgeons might fuse certain joints or reconstruct ligaments. This sacrifices some movement but greatly increases stability. The purpose is to stop repeated sprains and deformity progression, making walking safer, especially when braces alone are not enough.

3. Spinal surgery for scoliosis (selected cases) – If CMT-related muscle weakness leads to significant scoliosis, spinal fusion may be considered. Metal rods and screws straighten and stabilize the spine. The purpose is to prevent progression that could affect lung function or cause chronic pain.

4. Nerve decompression (rare, selected) – In a few cases, compressive lesions like tarsal tunnel or carpal tunnel on top of CMT are treated surgically by freeing the nerve from tight bands of tissue. This will not cure CMT but may relieve added compression symptoms in that nerve segment.

5. Kidney biopsy and, in advanced disease, transplantation – In CMTDIE with suspected FSGS, a kidney biopsy is done to confirm diagnosis and guide treatment. Later, if kidneys fail, some patients may receive a kidney transplant. The purpose is to replace lost kidney function while continuing to manage the neuropathy separately. NCBI+2Global Genes+2

---

Prevention

You cannot prevent being born with the INF2 mutation, but you can reduce complications:

1. Avoid clearly neurotoxic drugs (e.g., vincristine, certain chemotherapy agents) where possible. FDA Access Data+3cmtausa.org+3FDA Access Data+3

2. Protect feet with good shoes, daily skin checks, and nail care to avoid ulcers and infections.

3. Use AFOs or other supports early when recommended to prevent falls and deformity.

4. Keep body weight in a healthy range to reduce load on weak feet and joints.

5. Control blood pressure and follow kidney-protective advice if there is protein in the urine. NCBI+2Global Genes+2

6. Stay active with suitable exercises to preserve strength and cardiovascular fitness. Physiopedia+2nhs.uk+2

7. Avoid smoking and heavy alcohol use, which worsen vascular and nerve health.

8. Treat infections quickly, especially foot wounds and urinary infections, to protect nerves and kidneys.

9. Attend regular follow-ups with neurology, nephrology, physiotherapy, and other specialists.

10. Offer family members genetic counseling so that at-risk relatives can be monitored early.

---

When to see doctors urgently or for routine care

You should have regular planned visits with a neurologist (for CMT), a nephrologist (if kidney issues exist or proteinuria is detected), and rehabilitation specialists. However, urgent medical review is needed if:

• You notice sudden worsening of weakness, new difficulty walking, or repeated falls.

• There is new severe pain, burning, or numbness that appears quickly.

• You see foot sores, blisters, or ulcers that do not heal or become red, warm, or swollen.

• You have signs of kidney problems: swelling in the legs or face, frothy urine, very little urine, or high blood pressure symptoms like headaches or visual changes. NCBI+2Global Genes+2

• You are given a new medicine and then notice rapid worsening of nerve symptoms (possible drug toxicity). cmtausa.org+1

Routine reviews help adjust braces, manage pain safely, monitor kidney function, and update rehabilitation goals over time.

---

What to eat and what to avoid

There is no special “CMTDIE diet,” but a kidney- and nerve-friendly eating pattern can help overall health:

1. Eat plenty of vegetables and fruits (within kidney limits) to provide vitamins, minerals, and antioxidants that support general tissue health.

2. Choose whole grains instead of refined grains for sustained energy and fiber.

3. Include lean protein (fish, poultry, beans, lentils, eggs) in amounts recommended by your nephrologist; in advanced kidney disease, total protein may need adjustment.

4. Use healthy fats (olive oil, nuts, seeds, avocados) instead of trans fats and very fatty processed meats.

5. Limit salt (sodium) by reducing processed foods, fast food, and salty snacks, to protect blood pressure and kidneys. NCBI+2Global Genes+2

6. Avoid heavy alcohol because it can worsen neuropathy and damage liver and other organs.

7. Limit very sugary drinks and sweets, especially if there is also diabetes risk, to prevent extra nerve damage from high blood sugar.

8. Stay hydrated sensibly, following kidney doctor advice about fluid limits.

9. Be careful with high-dose herbal products or supplements without medical review, as some can harm kidneys or interact with medicines.

10. Work with a renal dietitian if FSGS or chronic kidney disease is present, to tailor potassium, phosphorus, and protein to lab results.

---

Frequently asked questions

1. Is autosomal dominant intermediate CMT type E curable?
No. At present, there is no cure that removes the INF2 mutation or fully restores damaged nerves. Treatment focuses on symptom control, preserving mobility, and protecting kidneys and other organs. Research into gene-targeted and disease-modifying therapies is ongoing. New England Journal of Medicine+3PMC+3ScienceDirect+3

2. Will everyone with this mutation get kidney failure?
No. Some people with CMTDIE have both neuropathy and FSGS, while others have only nerve disease or only kidney disease. The same INF2 mutations can appear in different patterns. Regular kidney check-ups help detect problems early. OUP Academic+4NCBI+4cmtausa.org+4

3. How fast does the disease progress?
Progression is usually slow over many years. Symptoms often start in childhood, teenage years, or early adulthood and gradually worsen. Many people stay able to walk, sometimes with braces or aids, though some eventually need wheelchairs for longer distances. Orpha+2Global Genes+2

4. Can exercise make the disease worse?
Appropriate, low-impact exercise supervised by professionals usually helps rather than harms. Over-training or high-impact sports that cause repeated injury may worsen pain or joint problems, but do not change the gene itself. Tailored programs balance activity and rest. Physiopedia+2nhs.uk+2

5. Is pregnancy safe for people with CMTDIE?
Many people with CMT have successful pregnancies. However, there may be more fatigue, balance problems, or pain. Kidney involvement needs special monitoring. Genetic counseling can help parents understand the 50% inheritance risk for each child. Obstetric and neurology teams can plan safe care. cmtausa.org+2Global Genes+2

6. Can children be tested for the gene?
Yes, genetic testing is possible where available, but whether and when to test minors is a complex family decision. Genetic counselors discuss benefits (early monitoring) versus psychological and insurance issues. NCBI+1

7. Do braces mean I will need a wheelchair?
Not necessarily. AFOs and other braces are often used to avoid early wheelchair use, by making walking safer and less tiring. Some people may still need wheelchairs for long distances or later in life, but many use braces as their main walking support. Pod NMD+2ScienceDirect+2

8. Is pain always severe in this condition?
Pain varies widely. Some people have mainly weakness and minimal pain, while others have burning or shooting neuropathic pain. With proper management (physiotherapy, neuropathic pain medicines, psychological support), pain can often be reduced to a more manageable level. PMC+1

9. Does this disease affect life expectancy?
Most people with CMT alone have near-normal life expectancy. When FSGS causes severe kidney failure and cardiovascular complications, life expectancy can be reduced without good treatment. Modern kidney care, including dialysis and transplantation, has improved outcomes. NCBI+2Global Genes+2

10. Are experimental treatments worth trying?
Enrolling in reputable clinical trials, run by academic centers and approved by ethics committees, can help advance knowledge and may offer access to promising therapies. However, unregulated “stem-cell clinics” or unproven treatments can be expensive and risky. Always discuss trials with your specialist team. CMT Research Foundation+6PMC+6ScienceDirect+6

11. Can diet alone treat CMTDIE?
No diet can change the INF2 mutation or fully repair damaged nerves. However, a healthy eating pattern supports muscle, bone, cardiovascular, and kidney health and can reduce complications such as obesity, high blood pressure, and poor wound healing.

12. Should I avoid all sports?
Total avoidance of movement is harmful. Many people continue with adapted sports such as swimming, cycling, or wheelchair sports. Contact sports or activities with high fall risk may need to be modified or avoided, depending on balance and weakness. Discuss safe options with physiotherapists.

13. What is the role of kidney biopsy?
If tests show significant protein in the urine and reduced kidney function, nephrologists may perform a kidney biopsy to confirm FSGS and rule out other causes. The result guides treatment decisions such as immunosuppressive therapy and transplant planning. NCBI+2Global Genes+2

14. Can siblings have different symptoms?
Yes. Even with the same INF2 mutation in the same family, one person may have mainly neuropathy, another may have kidney disease, and a third may have both. This is called variable expressivity and is common in genetic conditions. NCBI+3New England Journal of Medicine+3OUP Academic+3

15. Where can families find support?
Patient organisations for CMT and rare kidney diseases, such as national CMT associations and rare-disease networks, offer information, peer support, and updates on research and trials. These groups also provide practical advice about school, work, and social life with CMT. Wikipedia+4PMC+4ScienceDirect+4

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 24, 2025.